Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.LACQ · Entity 8108 | Sponsor Affiliate of the Co. | January 15, 2018 | January 17, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date January 15, 2018 · Filed January 17, 2018
Jointly reported with WEIL A LORNE
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 266,900 |
Reported balance
After 2018-01-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-01-15 · Other · Disposed 40,645 · Balance 266,900 F1: As contemplated by the securities subscription agreement between such reporting person and the Company, 40,645 shares held by Mr. Weil were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 867,842 |
Reported balance
After 2018-01-15 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-01-15 · Other · Disposed 132,158 · Balance 867,842 F2: As contemplated by the securities subscription agreement between such reporting person and the Company, 132,158 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. F3: Represents shares of common stock held by the Sponsor Affiliate. The shares held by the Sponsor Affiliate are beneficially owned by A. Lorne Weil, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate. Mr. Weil owns all of the membership interests in the Sponsor Affiliate. Mr. Weil disclaims beneficial ownership over any securities owned by the Sponsor Affiliate in which he does not have any pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: As contemplated by the securities subscription agreement between such reporting person and the Company, 40,645 shares held by Mr. Weil were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering.
F2: As contemplated by the securities subscription agreement between such reporting person and the Company, 132,158 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering.
F3: Represents shares of common stock held by the Sponsor Affiliate. The shares held by the Sponsor Affiliate are beneficially owned by A. Lorne Weil, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate. Mr. Weil owns all of the membership interests in the Sponsor Affiliate. Mr. Weil disclaims beneficial ownership over any securities owned by the Sponsor Affiliate in which he does not have any pecuniary interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2018 Filed Jan 17, 2018 17:35 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 132,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-000388 · s108741_form4.xml · nonDerivative · entry 2 WEIL A LORNE · CIK 0000921873 · Director · Executive Chairman Hydra LAC, LLC · CIK 0001723195 · Sponsor Affiliate of the Co. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 867,842 F2 · shares: As contemplated by the securities subscription agreement between such reporting person and the Company, 132,158 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. F2 · price: As contemplated by the securities subscription agreement between such reporting person and the Company, 132,158 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. F3 · ownership.nature: Represents shares of common stock held by the Sponsor Affiliate. The shares held by the Sponsor Affiliate are beneficially owned by A. Lorne Weil, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate. Mr. Weil owns all of the membership interests in the Sponsor Affiliate. Mr. Weil disclaims beneficial ownership over any securities owned by the Sponsor Affiliate in which he does not have any pecuniary interest. Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 17:35 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 40,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-000388 · s108741_form4.xml · nonDerivative · entry 1 WEIL A LORNE · CIK 0000921873 · Director · Executive Chairman Hydra LAC, LLC · CIK 0001723195 · Sponsor Affiliate of the Co. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,900 F1 · shares: As contemplated by the securities subscription agreement between such reporting person and the Company, 40,645 shares held by Mr. Weil were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. F1 · price: As contemplated by the securities subscription agreement between such reporting person and the Company, 40,645 shares held by Mr. Weil were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 18:56 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 169,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-062471 · tv480821_4.xml · nonDerivative · entry 2 WEIL A LORNE · CIK 0000921873 · Director · Executive Chairman Hydra LAC, LLC · CIK 0001723195 · Sponsor Affiliate of the Co. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,000,000 F3 · shares: As contemplated by the securities subscription agreement between such reporting person and the Company, 169,517 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate"), were forfeited upon consummation of the Company's initial public offering for no consideration. F3 · price: As contemplated by the securities subscription agreement between such reporting person and the Company, 169,517 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate"), were forfeited upon consummation of the Company's initial public offering for no consideration. F4 · balance_after: Includes an aggregate of 132,159 shares held by the Sponsor Affiliate that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not exercised. F5 · ownership.nature: Represents shares of common stock held by the Sponsor Affiliate. The shares held by the Sponsor Affiliate are beneficially owned by A. Lorne Weil, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate. Mr. Weil owns all of the membership interests in the Sponsor Affiliate. Mr. Weil disclaims beneficial ownership over any securities owned by the Sponsor Affiliate in which he does not have any pecuniary interest. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 18:56 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 187,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-062471 · tv480821_4.xml · nonDerivative · entry 1 WEIL A LORNE · CIK 0000921873 · Director · Executive Chairman Hydra LAC, LLC · CIK 0001723195 · Sponsor Affiliate of the Co. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,545 F1 · shares: As contemplated by the securities subscription agreement between such reporting person and the Company, 187,166 shares held by Mr. Weil were forfeited upon consummation of the Company's initial public offering for no consideration. F1 · price: As contemplated by the securities subscription agreement between such reporting person and the Company, 187,166 shares held by Mr. Weil were forfeited upon consummation of the Company's initial public offering for no consideration. F2 · balance_after: Includes an aggregate of 40,645 shares held by Mr. Weil that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not exercised. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.